The impact of HLA class I and EBV latency‐II antigen‐specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphoma

@inproceedings{Jones2016TheIO,
  title={The impact of HLA class I and EBV latency‐II antigen‐specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphoma},
  author={Ken A Jones and Leesa F Wockner and Rebekah M. Brennan and Ciara Keane and Pratip K. Chattopadhyay and Mario Roederer and David A. Price and David K Cole and Basma Hassan and Konstanze Beck and D. Gottlieb and D. Stuart Ritchie and John F Seymour and Frank Vari and Pauline Crooks and Scott R. Burrows and Maher K Gandhi},
  booktitle={Clinical and experimental immunology},
  year={2016}
}
In 40% of cases of classical Hodgkin lymphoma (cHL), Epstein-Barr virus (EBV) latency-II antigens [EBV nuclear antigen 1 (EBNA1)/latent membrane protein (LMP)1/LMP2A] are present (EBV(+) cHL) in the malignant cells and antigen presentation is intact. Previous studies have shown consistently that HLA-A*02 is protective in EBV(+) cHL, yet its role in disease pathogenesis is unknown. To explore the basis for this observation, gene expression was assessed in 33 cHL nodes. Interestingly, CD8 and… CONTINUE READING